Literature DB >> 7795274

Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.

M A Naylor1, G E Adams, A Haigh, S Cole, T Jenner, N Robertson, D Siemann, M A Stephens, I J Stratford.   

Abstract

RB 90740 is the lead compound in a series of aromatic mono-N-oxide bioreductive drugs. The compound shows considerably greater toxicity towards hypoxic verses aerobic mammalian cells in vitro. The differential in concentration required to give the same level of cell killing under these conditions ranges from 3.5 in a human bronchio-alveolar tumor cell line up to 120 in a rodent cell line defective in the repair of DNA strand breaks. The ability of RB 90740 to cause DNA strand breaks under hypoxic conditions was confirmed by alkaline sucrose gradient and pulsed field gel electrophoresis techniques. Despite these properties demonstrated in vitro, RB 90740 was shown not to be cytotoxic to hypoxic cells in experimental murine tumors in vivo. This may be due, in part, to the level of hypoxia (< 0.02% O2) necessary to produce toxicity in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795274     DOI: 10.1097/00001813-199504000-00010

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

Review 1.  Recent developments in the design of bioreductive drugs.

Authors:  W A Denny; W R Wilson; M P Hay
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Oncogenic potential of bifunctional bioreductive drugs.

Authors:  T K Hei; S X Liu; E J Hall
Journal:  Br J Cancer Suppl       Date:  1996-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.